The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AI-detected tumor-infiltrating lymphocytes and response to PD-1 based treatment in advanced melanoma.
 
Mark Schuiveling
No Relationships to Disclose
 
Isabella van Duin
No Relationships to Disclose
 
Laurens ter Maat
No Relationships to Disclose
 
Janneke van der Weerd
No Relationships to Disclose
 
Franchette van den Berkmortel
No Relationships to Disclose
 
Femke Burgers
No Relationships to Disclose
 
Marye Boers-Sonderen
No Relationships to Disclose
 
Alfonsus van den Eertwegh
Consulting or Advisory Role - Bristol Myers Squibb BV (Inst); Janssen Cilag BV (Inst); MSD oncology (Inst); Pierre Fabre (Inst)
Research Funding - Idera (Inst)
Travel, Accommodations, Expenses - Ipsen; Ipsen
 
Jan Willem de Groot
No Relationships to Disclose
 
John Haanen
Stock and Other Ownership Interests - Neogene Therapeutics
Consulting or Advisory Role - Achilles Therapeutics (Inst); AstraZeneca (Inst); bioNTech (Inst); Bristol-Myers Squibb (Inst); CureVac; Eisai (Inst); Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Ipsen (Inst); Molecular Partners (Inst); MSD Oncology (Inst); Neogene Therapeutics; Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Sastra Cell Therapy; T-Knife (Inst); Third Rock Ventures; Third Rock Ventures (Inst)
Research Funding - Amgen (Inst); Asher Biotherapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Geke Hospers
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Seerave Foundation (Inst)
 
Ellen Kapiteijn
Consulting or Advisory Role - Delcath Systems (Inst); Immunocore (Inst); Lilly (Inst)
Research Funding - BMS (Inst); Delcath Systems (Inst); Novartis (Inst); Pierre Fabre (Inst)
 
Djura Piersma
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Novartis (Inst); Pierre Fabre (Inst)
 
Gerard Vreugdenhil
No Relationships to Disclose
 
Hans Westgeest
Honoraria - Merck (Inst)
 
Anne Schrader
No Relationships to Disclose
 
Mitko Veta
No Relationships to Disclose
 
Willeke Blokx
No Relationships to Disclose
 
Paul van Diest
Consulting or Advisory Role - PAIGE.AI; Sectra; Visiopharm
Patents, Royalties, Other Intellectual Property - DDX3 as a biomarker for cancer and methods related thereto (Inst)
 
Karijn Suijkerbuijk
Honoraria - Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst)
Consulting or Advisory Role - Abbvie (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pierre Fabre (Inst); Sairopa (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Philips Healthcare (Inst); TigaTx (Inst)